Pre-Diabetes is a Predictor of Short-Term Poor Outcomes After Acute Ischemic Stroke Using iv Thrombolysis.: Pre-Diabetes Might Be an Alienated Area From Medical Attention Before Stroke Onset

Byoung-Gwon Kim
Dong-A University

Ga-Yeon Kim
Dong-A University

Jae-Kwan Cha (✉ nrcjk65@gmail.com)
Dong-A University

Research Article

Abstract

Backgrounds: Pre-diabetes is an intermediate state between normal glucose metabolism and diabetes. Recent studies suggest that the presence of pre-diabetes is associated with poor outcomes after AIS. However, the results have been controversial. This study examines whether pre-diabetes influences the patients' short and long-term outcomes for AIS using IV thrombolysis.

Methods: We enrolled 661 AIS patients with IV thrombolysis. Based on the 2010 ADA guidelines, patients were classified as pre-diabetes, with HbA1c levels of 5.7%–6.4%; diabetes, HbA1c levels more than 6.5%; and NGM (normal glucose metabolism), with HbA1c levels less than 5.7%. We investigated short-term outcomes, including early neurologic deterioration (END), in-hospital death, and poor functional outcomes (mRS>2) at 90days. As for long-term outcomes, poor functional outcomes were measured at 1 year.

Results: Of the 661 AIS patients treated with IV thrombolysis, 197 patients (29.8%) were diagnosed with pre-diabetes, and 210 (31.8%) were diagnosed with diabetes. In a multivariate analysis, pre-diabetes was an independent predictor for END (OR=2.02; 95% CI 1.12-3.62; p=0.02) and in-hospital death (OR=3.12; 95% CI 1.06-9.09; p=0.04). In contrast, diabetes was a significant independent factor for poor long-term outcomes (OR=1.75; 95% CI 1.09-2.78; p=0.02) after correcting confounding factors.

Conclusion: Unlike diabetes, pre-diabetes can be an important predictor of short-term outcomes after AIS. However, more detailed research is needed to specify the precise mechanisms by which pre-diabetes affects the prognosis of acute ischemic stroke.

Introduction

Diabetes is a well-known risk factor for stroke [1, 2] and a significant predictor for poor outcome after acute ischemic stroke [3-5]. Pre-diabetes, including impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) and/or impaired hemoglobin A1c (HbA1c), is an intermediate metabolic state between normal glucose metabolism and diabetes [6, 7].

Recent studies showed that pre-diabetes is associated with an increase of poor-outcome and mortality after acute ischemic stroke [8-10]. However, other reports did not observe a significant association between the presence of pre-diabetes and poor outcome after acute ischemic stroke after correcting several confounding factors [11, 12]. Also, only a few studies were able to identify the relationship between the long-term outcome and pre-diabetes in acute ischemic stroke.

In this study, we investigated the impacts of pre-diabetes on short-term (early neurologic deterioration, in-hospital death, and functional outcome at 90 days) and long-term outcomes (functional outcome at 1-year) after treating acute ischemic stroke with IV thrombolysis. Also, we observed how pre-diabetes and diabetes differently influence the outcomes in this population.

Methods

Study population

We performed a retrospective study that was approved by the Institutional Review Board and performed in accordance with the ethical standards of the 1964 Declaration of Helsinki and its later amendments, incorporating consecutive patients enrolled in CRCS-K registry [13].

We studied 3,400 patients with AIS prospectively registered in the CRCS-K registry of Dong-A university stroke center from 2015 into August 2018. Among them, we reviewed 669 (19.7%) patients using IV t-PA. After excluding eight patients due to missing data, 661 patients enrolled in this study.

Data acquisition

The baseline data collected from the patients included the National Institutes of Health Stroke Scale (NIHSS) score and the stroke subtype, which was stratified according to the TOAST classification after complete diagnostic profiling with some modifications.

Based on our stroke code system, we used intravenous tissue plasminogen activator (IV t-PA) within 4.5 hours of stroke onset [14]. This study collected the onset-to-needle time (OTN, from symptom onset to IV t-PA use).

Based on the 2010 ADA guidelines [6, 7], all AIS patients with HbA1c levels within the range of 5.7%–6.4% were classified as prediabetics, patients with HbA1c levels more than 6.4% were classified as diabetics, and patients with HbA1c levels less than 5.7% were classified as normal glucose metabolism (NGM). When the patients' initial blood glucose level measured in the emergency room was above 140 mg/dl, it was defined as hyperglycemia [15].

In this study, we set early neurologic deterioration (END), in-hospital death, and poor functional outcome at 90 days as short-term outcomes and considered poor functional outcomes at 1 year as long-term outcomes.

The definition of END followed the criteria set by the CRCS-K registry [3] as any new neurological symptoms/signs or neurological worsening that occurred within 3 weeks after the onset of index stroke. Aggravated neurological status includes 1) an increase in NIHSS score ≥2-point; 2) increase in NIHSS score 1a, 1b or 1c subscore ≥1-point; 3) increase in NIHSS score 5a, 5b, 6a, 6b (motor sub-score) ≥1-point; or 4) any kind of newly developed neurological symptom. The mRS scores were dichotomized into ≤2 (good functional outcome) and >2 (poor outcome). Outcomes were measured by three trained nursing staff coordinators independent of the study.

Statistical analysis

The clinical characteristics of the patients were summarized, and specific subgroups were described using descriptive statistics. After descriptive analyses, the categorical variables of the groups were compared using the Fisher's exact test or Pearson's chi-square test, while the continuous variables of the

groups were compared by using the Student's t-test and ANOVA test. In this study, the initial glucose level (³ 140 or <140 mg/dl) and NIHSS (³ 10 or <10 points) were considered as categorical parameters.

Univariate analyses were performed to identify the odds ratio across the outcome parameters (END, in-hospital death, poor functional outcome at 90 days and 1-year). Also, logistic analyses were performed with clinical variables and laboratory results. Potentially confounding variables included in the adjusted analysis were predefined: age, women, baseline NIHSS score, atrial fibrillation, TOAST classification, atrial fibrillation, previous stroke, door-to-needle time, endovascular therapy, and initial glucose level based on prior reports. The odds ratios (ORs) and 95% confidence interval (CI) were calculated. All P-values were 2-sided, and statistical significance was defined as a P-value less than 0.05. STATA/MP 16.1 (StataCorp., College Station, TX, USA) was used in all the statistical analyses.

Results

Among 661 AIS patients with IV thrombolysis, 197 patients (29.8%) were pre-diabetes, and 210 were diabetes (31.8%). Of the 210 patients with diabetes, 52 patients (7.9%) had unrecognized diabetes.

Table 1 compares baseline characteristics and clinical outcomes in patients with normal glucose metabolism, pre-diabetes, and diabetes. The prevalence of hypertension and hyperlipidemia was significantly higher in patients with diabetes than those with NGM or pre-diabetes. Also, initial hyperglycemia (³ 140mg/dl) was much higher in the diabetes group than in others. However, there was no considerable difference in age or stroke severity, expressed by NIHSS, among the three groups. Also, their rates of mechanical thrombectomy and onset to needle time were similar.

Regarding the short-term outcomes after acute ischemic stroke using IV thrombolysis, 126 patients (14.5%) experienced an END, 36 patients (5.4%) an in-hospital death, and 303 (45.8%) a poor outcome at 90 days. One-year after using IV thrombolysis, 297 patients (44.9%) showed a poor functional outcome measured by mRS (Table 1). The prevalence of END (p<0.05), in-hospital death (p<0.05), poor-outcome at 90 days (p<0.01), and 1-year (p<0.01) were significantly higher in patients with diabetes than in those with NGM. In the pre-diabetes population, the proportion of END (p<0.05) and in-hospital death (p<0.01) were significantly higher compared to the NGM population.

In a univariate analysis, pre-diabetes (p=0.02) and diabetes (p<0.01) were significantly associated with END. Regarding in-hospital death, it was significantly related to pre-diabetes (p<0.01), diabetes (p<0.01), age (p<0.01), women (p<0.01), initial stroke severity (p<0.01), and initial glucose level (p<0.01). As for poor outcome at 90 days, diabetes (p<0.01), age (p<0.01), women (p<0.01), hypertension (p<0.01), previous history of coronary artery disease (p<0.01), Atrial fibrillation (p<0.01), initial stroke severity (p<0.01), and initial glucose level (p<0.01) had a significantly higher odd for it. In the case of poor outcome at 1-year, it was severely influenced by diabetes (p<0.01), age (p<0.01), women (p<0.01), hypertension (p<0.01), atrial fibrillation (p<0.01), initial stroke severity (p<0.01), and initial glucose level (p<0.01).

In a multivariate analysis that controlled for relevant factors, the presence of pre-diabetes had an independent significance on the occurrence of END (OR=2.02; 95% CI 1.12-3.62; p=0.02) and in-hospital death (OR=3.12; 95% CI 1.06-9.09; p=0.04). In contrast, the presence of diabetes was a significant predictor for poor outcome at 1-year (OR=1.75; 95% CI 1.09-2.78; p=0.02) after correcting relating covariant. In this study, the presence of pre-diabetes predicted short-term outcomes such as END and in-hospital death. By comparison, diabetes was significant in predicting long-term outcome at 1-year after using IV thrombolysis in AIS. Initial glucose level more than 140 mg/dl (OR=2.54; 95% CI 1.15-5.59; p<0.01) was a significant predictor for in-hospital mortality (Table 2).

Discussion

The prevalence of diabetes in acute ischemic stroke was 31.8% in this study, similar to several other prospective stroke registry data [3,15, 16]. Also, among the patients diagnosed with diabetes, nearly 25% were so-called unrecognized diabetes, newly diagnosed by using HbA1C. Therefore, it has been recommended to check HbA1C or oral glucose tolerance test (OGTT) in all acute ischemic stroke patients, regardless of their previous history [17]. Among the recommended tests, HbA1C has an advantage over OGTT in identifying pre-diabetes in patients with an acute stroke unaffected by the acute-phase reaction [6]. Using HbA1C, the prevalence of pre-diabetes was 29.8% in our study, similar to previous reports. In this study, the presence of diabetes had a predictable value for the long-term outcome at 1-year but not for short-term outcomes.

Several previous results demonstrated that the presence of diabetes was significantly associated with END and worse outcomes at 90 days after acute ischemic stroke [5, 18]. However, in the Bichat stroke registry [4], the presence of diabetes had no impact on END and functional outcomes at 90 days in AIS using IV thrombolysis. Also, in the Lausanne Stroke Registry [19], there was no difference in short-term functional outcomes between stroke patients with and without diabetes. Differences in the patient population, functional outcome scales and follow-up duration may account for the contradictory results.

In particular, after acute stroke, short-term outcomes are primarily influenced by the patient's age and severity of stroke [20]. In our study, there were no differences of the age and stroke severity among three groups, so it was unlikely that the presence of diabetes would affect prognosis from the beginning of the stroke. In contrast, cardiovascular risk factors such as diabetes significantly impacted outcomes at least more than 90 days after AIS. This late-appearing pattern is probably related to the progression of the atherosclerotic vascular disease over time, which is known to be more rapid among diabetes. Also, the vascular risk profile among people with diabetes is worse because of their higher number of comorbidities and chronic conditions that result in accelerated atherosclerosis [21, 22]. In the Danish national stroke registry, diabetes did not affect patients' mortality with first ischemic stroke until 30 days; however, it began to affect it after 90 days and increased it significantly in 1 year [21]. Therefore, it is reasonable to conclude that diabetes affects the mid-to-long-term prognosis of acute stroke patients than their short-term outcomes.

Many previous studies showed that initial transient hyperglycemia higher than 140 mg/dl is an important predictor for in-hospital death after acute ischemic stroke using IV thrombolysis [2, 23, 24]. Our results also reaffirmed this notion. Data regarding the impact of transitory hyperglycemia on stroke mortality for more extended periods of follow-up are contradictory. 90 days after stroke onset, the mortality rate became almost equal between patients with transitory hyperglycemia and diabetes. Their rates did not differ after 180 or 365 days. Furthermore, upon admission, transient hyperglycemia was not an independent risk factor for one-year mortality after stroke [2, 25]. These reports indirectly support the authors' findings that transient hyperglycemia only affects the short-term prognosis after acute ischemic stroke.

In this study, pre-diabetes had a significant impact on the occurrence of END and in-hospital death after AIS using IV thrombolysis. Although a few previous studies suggested an association between the presence of pre-diabetes after acute stroke and worse outcomes [8-10], their relationship remains controversial [11, 12].

Generally, patients with pre-diabetes have an increased risk of type 2 diabetes and higher risks of cardiovascular diseases, such as stroke and recurrent stroke. Pre-diabetes, an intermediate metabolic state between normal glucose metabolism and diabetes, indicates an increased risk of developing type 2 diabetes and cardiovascular diseases in the future. Therefore, pre-diabetes should not be considered as a distinct clinical entity. Instead, it should be regarded as a continuum of increasing levels that represent growing risks of developing diabetes. Therefore, it is not logical to suggest that pre-diabetes and diabetes affect acute stroke in different directions.

In this data, AIS patients with pre-diabetes had a significantly lower prevalence of previous using statin (19.3% vs. 30.0 %, p<0.05, data are not shown) before AIS than those with diabetes. Also, the rate of previous using antiplatelet agents was lower in the pre-diabetes population than in the diabetes population. These data suggest that the pre-diabetes patients in our study may have been alienated from appropriate medical measures despite their risk of stroke occurrence. For this reason, they could have suffered more severe damages in the acute phase after stroke. Also, the increased hypercoagulable state in pre-diabetes patients without any interventions might have been critical for their early vascular instability [26, 27], consequently leading to END after AIS using IV thrombolysis. However, unlike diabetic patients, treatments such as using antiplatelet drugs immediately after an acute stroke and administering high doses of statins can ensure the stability of the vascular condition and have little effect on long-term prognosis.

Since only IV thrombolytic patients have been screened among AIS patients, this study has the advantage of reducing biases such as the onset time of stroke or treatment options that may affect long-term prognosis.

In this study, we proved that the presence of diabetes is associated with a worse long-term outcome after acute ischemic stroke. Also, we suggested that the presence of pre-diabetes may have an impact on the short-term outcome. A plausible reason may be the lack of interest in identifying pre-diabetes in the pre-

stroke stage. However, there is a limitation in the confirmation above because this study is not a detailed prospective study and involves a small number of patients. In a future research, a systematic review of the short-term and long-term prognosis for pre-diabetes in patients with acute ischemic stroke that uses a meticulous large-scale acute stroke registry will be needed.

Declarations

Availability of data and materials

The datasets generated and/or analyzed during the current study are not publicly available due for they are personal data but are available from the corresponding author on reasonable request.

Authors' contributions

BKK contributed to statistical analysis and interpretation of data, preparation and review of the manuscript. GYK contributed to patient data acquisition and review of the manuscript. JKC contributed to analysis and interpretation of data, preparation and review of the manuscript. All the authors have read and approved the final version of the manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable

Ethics approval and consent to participate

This study was approved by the Institutional Review Board of Dong-A University

Hospital. As this was a retrospective study, consent to participate was waivered.

References

1. The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010;

375:2215–22.

2. Mankovsky BN, Ziegler D 2004. Stroke in patients with diabetes mellitus. Diabetes Metab Res Rev 2004;20: 268–287.

3. Kim BJ, Park J-M, Kang KS, Lee SJ, Ko YC, Kim JG, Cha J-K, Kim D-H, Nah H-W, Han M-K, et al. Case characteristics, hyperacute treatment, and outcome information from the Clinical Research Center for Stroke-Fifth Division Registry in South Korea. J Stroke 2015; 17:38-53.

4. Desilles J-P, Meseguer E, Labreusche J, Labreche J, Lapergue B, Sirimarco G, Gonzalez-valcarcel J, Lavallee P, Calbrejo L, Guidox C, et al. Diabetes mellitus, admission glucose, and outcomes after stroke thrombolysis: A registry and systemic reviews. Stroke 2013; 44:1915-1923.

5. Megherbi S-E, Milan C, Minier D, Couvreir G, Osseby G-V Tilling K, Di Carlo A, Inzitari D, Wolfe CDA, Moreau T, et al. Association between diabetes and stroke subtype on survival and functional outcome 3 months after stroke: Data from the European BIOMED Stroke Project. Stroke 2003; 34:688-694.

6. Fonville S, Zandbergen AAM, Koudstaal PJ, den Hertog HM. Prediabetes in patients with stroke or transient ischemic attack: prevalence, risk and clinical management. Cerebrovasc Dis 2014; 37:393-400.

7. Mijajlović MD, Aleksić VM, Šternić NM, Mirkovic MM, Bornstein NM. Role of prediabetes in stroke. Neuropsychiatr Dis Treat 2017; 13:259-267.

8. Pan Y, Chen W, Wang Y. Prediabetes and outcomes of ischemic stroke or transient ischemic attack: A systemic review and meta-analysis. J Stroke Cerebrovasc Dis 2019; 28:683-692.

9. Marto JP, Saraiva M, Ladeira F, Sa F, Calado S, Viana-Baptista M. Prediabetes is associated with unfavorable outcome in young adult patients with ischemic stroke. J stroke Cerebrovasc dis 2018; 27:352-356.

10. Lei C, Wu B, Liu M, Chen Y. Association between hemoglobin A1C levels and clinical outcome in ischemic stroke patients with or without diabetes. J Clin Neurosci 2015; 22:498-503.

11. Tanaka R, Ueno Y, Miyamoto N, Yamashiro K, Tanaka Y, Shimura H, Hattori N, Urabe T. Impact of diabetes and prediabetes on the short-term prognosis in patients with acute ischemic stroke. J Clin Neurol Sci 2013; 332:45-50.

12. Forti P, Maioli F, Nativio F, Maestri L, Coveri M, Zoli. Association of pre-stroke glycemic status with stroke mortality. BMJ Open Diabetes Res Care 2020; 8: e000957.

13. Park HK, Kim BJ, Han MK, Park JM, Kang KS, Lee SJ, Kim JG, Cha J-K, Kim D-H, Nah H-W, et al ; CRCS-K Investigators. One-Year Outcomes After Minor Stroke or High-Risk Transient Ischemic Attack: Korean Multicenter Stroke Registry Analysis. Stroke. 2017;48(11):2991-2998.

14. Sohn SW, Park HS, Cha JK, Nah HW, Kim DH, Kang MJ, Choi JH, Huh JT. A systemized stroke code significantly reduced time intervals for using intravenous tissue plasminogen activator under magnetic resonance imaging screening. J Stroke Cerebrovasc Dis 2015;24(2): 465-472.

15. Tanne D, Koton S, Molshazki N, Goldbourt U, Shohat T, Tsabari R, Grossman E, Bornstein NM. Trends in management and outcome of hospitalized patients with acute stroke and transient ischemic

attack The National Acute Stroke Israeli (NASIS) Registry. Stroke 2012; 43:2136-2141.

16. Irie F, Kamouchi M, Hata J, Matsuo R, Wakisaka Y, Kuroda J, Ago T, Kitazono T, FSR investigators. Sex Differences in Short-Term Outcomes After AcuteIschemic Stroke, The Fukuoka Stroke Registry. Stroke 2015; 46:471-476.

17. Mapoure YN, Ba H, Ayeah CM, Ken,egne C, Luma HN, Njamnshi AK. Acute stroke patients with newly diagnosed diabetes mellitus have poorer outcomes than those with previously diagnosed diabetes mellitus. J Stroke Cerebrovasc Dis 2018; 27:2327-2335.

18. Lee S-J, Hong JM, Lee SE, Kang DR, Ovbiagele B, Demchuk AM, Lee JS. Association of fibrinogen level with early neurological deterioration among acute ischemic stroke patients with diabetes. BMC Neurology 2017; 17:101.Karapanayiotides T, Piechowski-Jozwiak B, van Melle G, Bogousslavsky J, Deuvyst G. Stroke patterns, etiology, and prognosis in patients with diabetes mellitus. Neurology 2004; 62:1558–1562.

19. Kamalesh M, Shen J, Eckert GJ. Long term postischemic stroke mortality in diabetes: A veteran cohort analysis. Stroke 2008; 39:2727-2731.

20. Anderson KK, Anderson ZJ, Olsen TS. Predictors of early and late case-fatality in national wide Danish study of 26818 patients with first-ever ischemic stroke. Stroke 2011; 42:2806-3812.

21. Palacio S, McClure LA, Benavente OR, Bazan 3rd C, Pergoloa P, Hart RG. Lacunar strokes in patients with diabetes mellitus: risk factors, infarct location, and prognosis: the secondary prevention of small subcortical strokes study. Stroke 2014; 45:2689-2694.

22. Weir CJ, Murrary GD, Dyker AG, Lees KR. Is hyperglycaemia an independent predictor of poor outcome after acute stroke? Results of a long-term follow up study. BMJ 1997;314:1303-1306.

23. Luitse MJA, Biessels GJ, Rutten GEHM, Kapelle LJ. Diabetes, hyperglycaemia, and acute ischaemic stroke. Lancet Neurol 2012; 11:261-271.

24. Szczudlik A, Slowik A, Turaj W. Transient hyperglycemia in ischemic stroke patients. J Neurol Sci et al. 2001; 189:105–111.

25. DeFronzo RA, Abdul-Ghani M. Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose. Am J Cardiol2011;108:3B–24B.

26. Ozkul A, Turgut ET, Akyol A, Yenisey C, Kadikoylu G, Tataroglu C, Kiylioglu N. The relationship between insulin resistance and hypercoagulability in acute ischemic stroke. Eur Neurol 2010; 64:201–6.

Tables

Table 1. Baseline characteristics

	NGM (=254)	Pre-DM (=197)	DM (=210)	*p*
Age	66.9 (13.7)	68.7 12.6	70.7 10.0	0.27
Female (%)	99 (38.9)	82 (41.6)	82 (39.1)	
Hypertension (%)	135 (53.2)	110(55.8)	152 (72.4)	<0.01
Smoking (%)	40 (15.8)	31 (15.7)	42 (20.0)	0.25
Hyperlipidemia (%)	42 (16.5)	39 (19.8)	86 (41.0)	<0.01
Prior CAD (%)	29 (11.4)	31 (15.7)	39 (18.6)	0.09
Atrial fibrillation (%)	95 (37.4)	88 (44.7)	78 (37.1)	0.2
Prior stroke (%)	24 (9.5)	22 (11.2)	34 (16.2)	0.08
TOAST classification				0.48
Large artery atherosclerosis (%)	54 (21.3)	45 (22.8)	59 (28)	
Cardioembolism (%)	95 (37.4)	85 (43.2)	74 (35.2)	
Small vessel occlusion (%)	36 (14.2)	20 (10.2)	20 (9.5)	
Other (%)	5 (2.0)	3 (1.5)	3 (1.4)	
Undetermined (%)	64 (25.2)	44 (22.3)	54 (25.7)	
NIHSS (median)	9	10	9	
NIHSS ³ 10 (%)	129 (50.8)	117 (59.4)	114 (54.3)	0.91
Initial glucose	125.4 25.7	133.9 42.1	177.7 70.6	<0.01
Initial glucose ³ 140 (%)	60 (23.6)	56 28.4	132 62.9	<0.01
OTN (min, mean SD)	153.9 119.9	155.5 122.7	178.4 170.1	0.82
Endovascular Tx (%)	84 (33.1)	64 (32.5)	69 (32.9)	0.99
END (%)	24 (9.5)	33 (16.8)	38 (18.1)	0.02
In hospital death (%)	5 (2.0)	14 (7.1)	17 (8.1)	<0.01
poor outcome-90days (%)	97 (38.2)	87 (44.2)	119 (56.7)	<0.01
poor outcome -1 year (%)	91 (35.8)	87 (44.2)	119 (56.7)	<0.01

NGM- Normal glucose metabolism, DM- Diabetes mellitus, CAD- Coronary artery diseases,

TOAST- Trial of Org 10172 in Acute Stroke Treatment, OTN- Onset to needle, END- Early neurological deterioration,

Table 2. Univariate and multivariate analysis for short- and long-term outcomes after AIS
Using IV thrombolysis

	Univariate (95% CI)	OR	Multivariate (95% CI)	Adjusted OR
END				
Pre-diabetes	1.20-3.38	1.92	1.12-3.62	2.02
Diabetes	1.22-3.66	2.11	0.83-2.92	2.02
Initial hyperglycemia	0.98-2.37	1.53	0.83-2.29	1.38
In-hospital death				
Pre-diabetes	1.34-10.76	3.8	1.06-9.09	3.12
Diabetes	1.59-12.10	4.38	0.83-7.60	2.52
Initial hyperglycemia	1.75-7.29	3.59	1.15-5.59	2.54
Poor outcome at 90 days				
Pre-diabetes	0.88-1.86	1.58	0.63-1.51	0.98
Diabetes	1.45-3.07	2.11	0.97-2.45	1.54
Initial hyperglycemia	1.30-2.45	1.79	0.91-2.00	1.35
Poor outcome at 1-year				
Pre-diabetes	0.97-2.07	1.41	0.73-1.75	1.13
Diabetes	1.61-3.40	2.34	1.09-2.78	1.75
Initial hyperglycemia	1.28-2.41	1.76	0.86-1.89	1.27

Adjusted for age, women, baseline NIHSS, atrial fibrillation, TOAST classification, previous stroke, onset to needle time, and endovascular therapy

CI- confidential interval, END- early neurologic deterioration, initial hyperglycemia- more than 140mg/dl,